Healthy Aging
Red light therapy for longevity and healthy aging
Aging is not one problem - it is several, operating in parallel. Mitochondrial decline, chronic low-grade inflammation, metabolic drift, and cognitive slowdown each accelerate the others. Here is what the clinical research actually shows about whether red light therapy can address any of them.
The short version
Red light therapy addresses several of the core biological mechanisms of aging - particularly mitochondrial decline and chronic inflammation - with genuine clinical evidence. For skin aging, the RCT data is strong. For metabolic health, a landmark 2024 UCL study showed a 27.7% reduction in post-meal blood glucose spikes using a 15-minute session. For cognitive aging, transcranial near-infrared light shows meaningful early results in dementia trials. The honest caveat: no human trial has yet measured whether any of this translates into longer lifespan or a lower biological age by an epigenetic clock. It addresses the upstream drivers of aging clearly; whether that extends healthspan in a measurable way requires larger, longer trials that are currently underway.
The four drivers of biological aging
Modern geroscience has moved away from thinking of aging as one process and towards identifying the underlying biological drivers that can be measured, and potentially slowed. Four stand out as both well-evidenced and relevant to what red and near-infrared light can plausibly affect.
Mitochondria produce less ATP as we age, while generating more damaging reactive oxygen species. This energy deficit affects every tissue in the body - muscle, skin, brain, metabolic organs.
A persistent, low-grade inflammatory state that accumulates with age. Unlike acute inflammation, it does not resolve. Over decades it drives cardiovascular disease, neurodegeneration, and metabolic decline.
Cells that stop dividing but refuse to die. Senescent cells accumulate in tissues and secrete pro-inflammatory signals, accelerating the aging of surrounding healthy cells.
Blood glucose regulation becomes progressively less efficient with age. Frequent glucose spikes cause glycation damage - a direct contributor to tissue aging, vascular stiffening, and cognitive decline.
Red and near-infrared light does not address all four equally. The evidence is strong for mitochondrial restoration and anti-inflammatory signalling, solid for skin and metabolic outcomes, and emerging for cognitive protection. Each is covered below with its clinical evidence.
Mitochondrial decline - the root cause
The mitochondria are the primary target of red and near-infrared light, and the reason photobiomodulation is relevant to aging at all. Cytochrome c oxidase - an enzyme in the mitochondrial respiratory chain - absorbs light in the red and near-infrared spectrum, triggering a cascade of downstream effects replicated at both cellular and clinical levels.
This is not speculative. The mechanism was identified in the 1980s by Tiina Karu at the Russian Academy of Sciences and has been replicated and refined across hundreds of studies since. Jeffery's group at UCL published foundational work showing 670nm red light restores mitochondrial membrane potential and ATP output - including Begum et al. 2015 in Biology Letters - the same research programme that led directly to the blood glucose findings published in 2024.
What mitochondrial decline actually does
As mitochondria age, three things happen simultaneously: ATP production falls, reactive oxygen species (ROS) output rises, and mitochondrial membrane potential weakens. The result is a cell that cannot power its own repair processes, while being progressively damaged by the oxidative stress it generates. This is the upstream cause of skin thinning, slower wound healing, muscle loss, impaired glucose clearance, and cognitive slowdown - not separate diseases, but the same root process expressing itself across different tissues.
The key insight: Because mitochondrial dysfunction is a shared upstream driver of so many aging processes, restoring mitochondrial function has the potential to produce downstream benefits across multiple tissues simultaneously. This is why the same mechanism appears in the skin, metabolic, and cognitive evidence - it is one pathway with many expressions.
NIR light and mitochondrial depth
Red light (630-660nm) reaches mitochondria in skin and superficial tissues effectively. Near-infrared light (810-850nm) penetrates several centimetres deeper - reaching muscle, joint tissue, and crucially, brain tissue when applied transcranially. This depth distinction matters significantly for the cognitive aging evidence discussed later. The 9-wavelength spectrum in NovaThera devices covers both red and NIR ranges specifically to address this - different tissue depths require different wavelengths.
Inflammaging - chronic low-grade inflammation
The term "inflammaging" was coined by researcher Claudio Franceschi to describe the chronic, low-grade inflammatory state that accumulates with age - distinct from the acute inflammation that heals injuries and resolves within days. Inflammaging is persistent, systemic, and silently destructive. Its effects on reproductive aging and egg quality are covered in depth in our fertility and mitochondrial health guide. It is now considered a primary driver of cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer risk in older adults.
Red light therapy has measurable anti-inflammatory effects, and this is one of the most consistently replicated findings in the photobiomodulation literature.
How it works on inflammation
Three mechanisms are relevant. First, by restoring mitochondrial function, red light reduces oxidative stress - a major trigger for the pro-inflammatory NF-kB signalling pathway. Second, red light promotes the release of nitric oxide from mitochondrial membranes, which causes vasodilation and improves blood flow, allowing inflammatory mediators to clear more efficiently. Third, direct modulation of immune cells - particularly macrophages - shifts them from a pro-inflammatory M1 phenotype towards an anti-inflammatory M2 phenotype.
A 2025 comprehensive immunomodulatory review in Lasers in Medical Science (PMC11991943) analysed studies from 2000 to 2024, covering PBM's effects across immune cell types. The evidence for anti-inflammatory effects across macrophages, dendritic cells, and T-cells was described as consistent and mechanistically well-understood. A 2025 umbrella review of PBM across multiple health outcomes (Systematic Reviews, PMC12326686) - drawing from meta-analyses of RCTs - confirmed significant positive effects for pain and inflammation across diverse clinical conditions.
The dose-response caveat
Photobiomodulation follows a biphasic dose-response curve - meaning too little light produces minimal effect, but too much can blunt or reverse the benefit. The anti-inflammatory effects reviewed in the literature are dose-dependent. This is why irradiance specifications, treatment duration, and distance from device matter. Devices without published irradiance data cannot reliably reproduce clinical outcomes.
Inflammaging and the aging skin connection
Skin aging is partly a collagen production problem and partly an inflammation problem. For a deeper look at how these same pathways affect hair follicles, see our red light therapy for hair loss guide. Chronic low-grade inflammation in the dermis accelerates collagen degradation, reduces fibroblast activity, and impairs the skin barrier. This is why anti-inflammatory treatment and collagen-stimulating treatment are the same treatment in red light therapy - both trace back to the same mitochondrial and inflammatory pathways.
Skin aging - the strongest clinical evidence
If you want the most robust clinical evidence for red light therapy's effect on any aging process, skin is the place to look. It is the most studied application, it has the longest evidence trail, and it is where multiple independent RCTs have converged on consistent results.
What the trials show
Wunsch and Matuschka (2014, PMC3926176) conducted a randomised controlled trial with 136 volunteers using full-body red or polychromatic light in the 570-850nm range, with 30 sessions over approximately 15 weeks. Compared with untreated controls, treated participants showed significantly improved skin complexion, reduced roughness measured by profilometry, and increased intradermal collagen density confirmed by objective measurement. Both the skin improvement and collagen increase were statistically significant and visible to blinded expert reviewers.
A 2025 multi-centre double-blind RCT published in Medicine (Park, Park and Jung, doi: 10.1097/MD.0000000000041596) specifically targeted crow's feet using a combined 630nm LED and 850nm IRED mask in 60 participants. The experimental group showed significant improvement in crow's feet grading scale scores versus the sham-controlled group. No adverse effects were reported.
The mechanism is fibroblast stimulation. Fibroblasts are the cells responsible for producing collagen and elastin. The same fibroblast-stimulation mechanism is central to the evidence in our menopause and skin aging guide. Red and NIR light energises them via the mitochondrial pathway - more ATP, more synthetic activity, more structural protein output. It also stimulates hyaluronic acid production, which accounts for the improvement in skin hydration and plumpness reported consistently across studies.
Realistic expectations
The clinical improvements are real but measured. You are not looking at the results of ablative laser resurfacing. Across trials, improvements are typically described as softening and smoothing of wrinkles, increased firmness, improved texture, and a more even complexion. Participants and blinded reviewers both notice. The changes require consistent use over 8-16 weeks to become apparent, and require ongoing maintenance - collagen production does not sustain itself independently once treatment stops.
Metabolic health and blood glucose
Blood glucose management is not just a diabetes concern - it is one of the most direct aging interventions available to anyone. Frequent glucose spikes drive glycation, the process by which glucose attaches to proteins and fats, forming advanced glycation end-products (AGEs). AGEs accumulate in collagen, arteries, and neural tissue, stiffening structures and accelerating biological aging. This is a core driver of skin aging, cardiovascular aging, and cognitive decline - and it happens in everyone, not just diabetics.
This is where one of the most striking recent findings sits, and it comes from a UK institution. In February 2024, Dr Michael Powner (City, University of London) and Professor Glen Jeffery (UCL Institute of Ophthalmology) published a randomised trial in the Journal of Biophotonics showing that a single 15-minute exposure to 670nm red light on the upper back produced a 27.7% reduction in post-meal blood glucose levels and a 7.5% reduction in peak glucose spiking.
The mechanism is mitochondrial. Red light at 670nm increases ATP production in skeletal muscle cells, which accelerates glucose uptake and utilisation. The muscle - the largest glucose sink in the body after a meal - processes glucose faster when its mitochondria are energised by light.
Why the UCL finding matters for aging
Professor Jeffery noted that modern LED lighting - now dominant in UK homes and offices - is heavily weighted towards blue wavelengths with almost no red or near-infrared component. He described this as making people "red-starved" - a term that reflects a genuine shift in the light environment humans live under compared to natural sunlight, which contains a balanced red-to-blue ratio. The implications for metabolic health of this shift are now being studied actively.
Evidence status: The Powner-Jeffery 2024 study was conducted in 30 healthy participants, not diabetic individuals. The authors were explicit that a bridge to diabetic subjects has not yet been made. Oxford professors commenting in Medscape described the findings as promising but the clinical application as "a long way off" from diabetes management. We present this accurately: the mitochondrial mechanism is sound, the glucose result is compelling, and the translation to therapeutic use requires larger trials - which are now in progress.
The blue light connection
The UCL team's work also highlights something broader. Sunlight historically provided a continuous spectrum including substantial red and NIR components. Modern indoor LED lighting is predominantly blue with minimal red. At a cellular level, blue light and red light have opposing effects on cytochrome c oxidase - red light activates it, blue light in high doses inhibits it. The researchers suggested that chronic blue-light dominance in modern environments may be contributing to the background decline in mitochondrial function seen across populations, including the rising prevalence of metabolic dysfunction. This is an area of active research rather than established fact - but the mechanistic argument is well-grounded.
Cognitive aging and brain health
The brain is the most metabolically active organ in the body. Neurons have among the highest mitochondrial density of any cell type. The same mitochondrial restoration mechanism is explored in our testosterone and hormonal health guide. This makes the brain both particularly vulnerable to age-related mitochondrial decline and, potentially, particularly responsive to therapies that restore mitochondrial function.
Near-infrared red light therapy (810-850nm) can penetrate the skull and reach cortical brain tissue - this has been confirmed by cadaver studies measuring light distribution. Transcranial photobiomodulation is an active area of clinical research with a growing body of trial data.
Clinical trial results for cognitive aging
A 2024 systematic review by Rodríguez-Fernández, Zorzo and Arias (GeroScience, PMID 38861125) synthesised preclinical and clinical evidence for PBM during aging across healthy and pathological conditions. The review covered animal models and human trials, assessing cognitive, emotional, and brain-structural outcomes. The conclusion: PBM shows "promising results in the treatment or prevention of age-related cognitive impairments" - with the caveat that human trial numbers remain relatively small and protocols are not yet standardised.
A double-blind, placebo-controlled RCT (PMC8219492) treated 60 patients with mild to moderate dementia using transcranial NIR stimulation twice daily for 8 weeks. Active treatment produced significant improvements in MMSE scores (+4.4 versus +1.0 in the sham group, p=0.0253) and Activities of Daily Living scores (-3.6 versus +3.1, p=0.0437). Patients and caregivers in the active group reported noticeable improvement in cognitive function and daily activities. No adverse effects were recorded.
A 2025 Frontiers in Neurology RCT using 630nm red light in post-stroke cognitive impairment patients (90 enrolled, 82 completing) showed significant improvements in cognitive scores and neuropsychiatric symptoms compared to the control group. The researchers proposed a formaldehyde-clearing mechanism - red light appears to help neurons clear metabolic waste products that accumulate with age and after neurological injury.
Important context on the cognitive evidence
The cognitive trials to date have focused primarily on impaired populations - dementia patients and post-stroke patients - rather than healthy aging adults seeking to preserve function. The evidence that transcranial PBM can slow normal age-related cognitive decline in healthy older adults is not yet established in RCTs. The mechanism is sound, trials in healthy populations are recruiting, and the results in impaired populations are encouraging - but extrapolating to prevention requires care.
The formaldehyde connection
One of the more intriguing recent findings in this area: brain formaldehyde accumulates with age and has been associated with age-dependent memory decline. It is a metabolic byproduct that healthy, well-functioning neurons normally clear. When mitochondrial function declines, clearance slows. The 2025 Frontiers in Neurology study found that red light therapy improved cognitive outcomes in parallel with measurable improvements in formaldehyde metabolism - suggesting that part of red light's brain benefit may involve restoring the cellular energy needed for neurotoxic waste clearance.
Evidence summary by aging domain
The evidence for red light therapy in longevity and aging is not uniform. It is strong in some areas, good in others, and emerging in a few. Here is an honest grading.
What it can and cannot do
Where the evidence supports it
- Stimulate collagen and elastin production in aging skin
- Restore mitochondrial ATP output in depleted cells
- Reduce chronic inflammation via cytokine and immune cell modulation
- Reduce post-meal blood glucose spikes
- Improve cognitive function in dementia and post-stroke populations
- Combine effectively with other interventions - exercise, sleep, nutrition
Where the evidence does not yet reach
- Reverse advanced biological aging or measurably reduce epigenetic age
- Extend lifespan - no human data exists
- Replace the fundamentals: sleep, nutrition, movement, stress management
- Produce results without consistent, long-term use
- Regenerate fully senescent tissue (scarring, advanced atrophy)
Key takeaways
- Aging has four primary biological drivers - mitochondrial decline, inflammaging, cellular senescence, and metabolic drift. Red light therapy has credible evidence for the first two, and solid emerging evidence for metabolic effects.
- Mitochondrial restoration is the foundation - all downstream benefits of red light therapy in aging trace back to cytochrome c oxidase activation and increased ATP production. This is the best-understood mechanism in the field.
- Skin aging has the strongest RCT evidence - multiple independent trials confirm collagen density increases, wrinkle reduction, and improved skin texture with consistent use over 8-15 weeks.
- The UCL blood glucose finding is significant - a 27.7% reduction in post-meal glucose spikes from a 15-minute, 670nm session is a meaningful metabolic effect. The researchers are UK-based and the study was published in a peer-reviewed journal. Larger trials are needed.
- Cognitive evidence is promising but targeted - RCTs in dementia and post-stroke patients show real improvements. The same results in healthy aging adults have not yet been demonstrated in controlled trials, though the mechanism supports it.
- No human trial has measured longevity extension - claims that red light therapy extends lifespan or reduces biological age by an epigenetic clock are mechanistically plausible but not yet supported by trial data. This does not diminish the real evidence that exists; it just means those specific claims are premature.
- Dual-wavelength devices matter - red (630-660nm) targets skin and superficial tissue; NIR (810-850nm) reaches muscle, deep tissue, and brain. For systemic aging applications, both ranges are relevant.
- Consistency and dosing are essential - the biphasic dose-response curve means too little light produces minimal effect and too much can reverse benefit. Irradiance, treatment duration, and treatment frequency all need to be within the ranges demonstrated in clinical trials.
Clinical sources and references
Mitochondrial and mechanism research
Skin aging clinical trials
Cognitive aging and brain health
Umbrella reviews and systematic evidence
NovaThera 9-Wavelength Devices
Covering both red (630-660nm) and near-infrared (810-850nm) ranges - the wavelengths with the strongest evidence across skin, metabolic, and systemic aging applications.